Splicing Dysregulation Impacts on Neuroendocrine Tumors: Evidence from Altered Spliceosoma Components and Somatostatin and Ghrelin Systems.

#1566

Introduction: Splicing is an emerging cancer hallmark influencing multiple tumor cell (dys)functions. We have shown that aberrantly spliced variants of somatostatin receptor subtype 5 (sst5TMD4) and of the pleiotropic neuropeptide ghrelin (in1ghrelin) are linked to poor prognosis in gastroenteropancreatic neuroendocrine tumors (GEPNETs) and may enhance their aggressiveness features.

Aim(s): We hypothesized that alterations in the splicing machinery can contribute to generate these abnormal variants, and offer novel intervention points in GEPNETs.

Materials and methods: To ascertain this question, an array of selected components of the major (n=13) and minor spliceosome (n=4), and associated splicing factors (n=28) was devised, and their levels of expression were evaluated using a Fluidigm methodology, in a series of 20 pancreatic NETs samples (47% G1, 47% G2 and 6% G3) and control-adjacent non-tumoral tissues.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Castaño J

Authors: Castaño J, Pedraza-Arevalo S, Herrea-Martinez A, Del Río-Moreno M, Sánchez-Sánchez R,

Keywords: Splicing,